PRP Hair Restoration: The Stage-by-Stage Candidacy Guide

Introduction: Why PRP Hair Restoration Requires a Candidacy-First Conversation

Hair loss affects more than 80 million people in the United States, and androgenetic alopecia (AGA) is by far the most common cause. Over a lifetime, AGA impacts up to 80% of Caucasian males and roughly 50% of females. It is one of the most widespread medical conditions in the country, and it carries a psychological weight that far exceeds its physical footprint.

Interest in Platelet-Rich Plasma (PRP) therapy has surged in response. Data from the International Society of Hair Restoration Surgery (ISHRS) shows a 25% year-over-year increase in PRP adoption across US clinics as of 2025, driven by both a maturing body of clinical evidence and rising patient demand for natural, regenerative options.

Yet PRP is neither a universal cure nor an unproven fad. Its effectiveness is deeply stage-dependent, and understanding where a person falls on a clinical scale is the single most important first step in evaluating the treatment honestly. This guide maps hair loss stages to PRP’s realistic success rates, explains where PRP fits within a tiered treatment hierarchy, and explores PRP’s underreported role as a surgical adjunct rather than a standalone therapy. The tone throughout is one of clinical honesty: readers will learn both what PRP can and cannot do, so they can make informed decisions instead of chasing unrealistic expectations.

What Is PRP Hair Restoration? The Science Behind the Treatment

PRP, or Platelet-Rich Plasma, is an autologous preparation derived from the patient’s own blood. A small blood sample is drawn and processed in a centrifuge to concentrate platelets to roughly four to eight times normal levels. This concentrate is then injected into the scalp to stimulate dormant hair follicles.

The biological mechanism centers on growth factors. Upon activation, platelets release a spectrum of signaling proteins, including Fibroblast Growth Factor (FGF), Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF), and Transforming Growth Factor-beta (TGF-beta). Together, these growth factors and cytokines stimulate cell proliferation, angiogenesis, and collagen synthesis, helping to stimulate hair follicles, prolong the anagen phase, and reduce scalp inflammation.

For hair specifically, these growth factors prolong the anagen (active growth) phase, prompt dormant follicle stem cells to shift from a resting to an active state, improve scalp microcirculation, and may increase hair shaft thickness.

The evidence base has grown substantially. A landmark 2025 systematic review and meta-analysis in Dermatology and Therapy analyzed 43 randomized controlled trials involving 1,877 participants and confirmed that activated PRP effectively increases hair density and minimizes recurrence compared with placebo. A 2025 Phase I clinical trial published through the NIH found that hair count increased by approximately 62.4% and hair thickness improved by 58.6% in the PRP injection group after two treatment sessions. Other clinical data shows an average increase of roughly 45.9 hairs per square centimeter after three initial treatments, with improvements continuing for up to 12 months.

A defining advantage is safety. Because PRP is derived from the patient’s own blood, the risk of allergic reaction or rejection is minimal, a key differentiator from pharmaceutical or synthetic treatments.

Activated vs. Non-Activated PRP: The Distinction Most Clinics Don’t Explain

Not all PRP is prepared or administered identically. This is one of the most clinically significant variables, and most patient-facing content ignores it entirely.

PRP can be administered in its native state (non-activated) or activated using agents such as calcium chloride or thrombin, which trigger immediate platelet degranulation and growth factor release. The 2025 meta-analysis found that activated PRP was associated with superior outcomes in increasing hair density, while non-activated PRP was associated with a higher frequency of adverse effects. That is a clinically important distinction.

Activation is only one of several preparation variables. Centrifugation speed, targeted platelet concentration, and injection depth all directly influence results. The ISHRS openly acknowledges a critical lack of standardization across the field: there are dozens of preparation permutations and no universally accepted protocol. This makes provider transparency about their specific approach a genuine quality indicator.

Prospective patients should ask direct questions: Do you use activated PRP? What centrifugation protocol do you follow? What platelet concentration do you target? These questions separate experienced, evidence-based providers from those following inconsistent or outdated protocols.

A practice like Shapiro Medical Group, which has focused exclusively on hair restoration since 1990 and whose founder co-authored the field’s definitive textbook, approaches these protocol decisions with the depth of expertise the variables demand.

The Clinical Stage-Mapping Framework: Are You a PRP Candidate?

The Norwood Scale (for men) and the Ludwig Scale (for women) are the clinical tools used to classify hair loss severity. They are the most important starting point for any PRP candidacy assessment.

The core clinical truth is simple: PRP induces follicle stem cells to shift from a dormant state to an active state that starts the process of hair production. It cannot regenerate follicles that have been permanently lost. This biological reality is what makes stage assessment non-negotiable.

PRP Candidacy by Norwood Stage (Male Pattern Hair Loss)

• Norwood I–II (Minimal Recession): PRP is highly appropriate as a preventive and maintenance strategy. Follicles are active and responsive, PRP can prolong the anagen phase and slow progression, and these patients are ideal candidates for standalone therapy.
• Norwood III–III Vertex (Early-to-Moderate Loss): This is the primary sweet spot for PRP. Clinical success rates of 70–80% are achievable, and PRP can meaningfully improve density, thickness, and coverage. Combination with medical therapies (minoxidil, finasteride) is strongly recommended for optimal outcomes.
• Norwood IV (Moderate Loss): PRP remains beneficial but expectations must be calibrated. Combination therapy becomes increasingly important, surgical consultation should be introduced as a parallel conversation, and PRP may serve as a pre-surgical scalp primer.
• Norwood V–VI (Advanced Loss): Success rates drop to 30–40%. PRP alone is unlikely to produce satisfying cosmetic results. Its most appropriate role here is as an adjunct to FUE hair transplantation, not as a standalone solution.
• Norwood VII (Severe Loss): PRP as a standalone treatment is generally not recommended. Surgical restoration becomes the primary intervention, and PRP’s role shifts entirely to a surgical adjunct that improves graft survival and accelerates post-operative recovery.

Notably, the ISHRS 2025 Census reported that 95% of first-time hair restoration surgery patients in 2024 were ages 20 to 35, reflecting a strong shift toward earlier intervention. This makes Norwood I–III patients a particularly important demographic for PRP as a first-line regenerative option. Patients considering their options at this stage may also find it useful to explore whether a hair transplant is worth the investment as part of a broader treatment conversation.

PRP Candidacy by Ludwig Stage (Female Pattern Hair Loss)

Female hair loss typically follows a diffuse thinning pattern (the Ludwig Scale) rather than the receding hairline common in men. PRP’s mechanism applies equally well to androgenetic alopecia in women.

• Ludwig I (Mild Diffuse Thinning): Excellent candidacy. Follicles are miniaturized but active, and PRP can reverse miniaturization, improve density, and extend the growth phase.
• Ludwig II (Moderate Diffuse Thinning with Widening Part): Strong candidacy. A 2024 systematic review covering 21 studies and 628 participants confirmed PRP effectively enhances hair density and thickness in women with a favorable safety profile. Combination with topical minoxidil is recommended.
• Ludwig III (Advanced Diffuse Thinning): Candidacy diminishes significantly. As with advanced male pattern loss, success rates fall when follicle populations are severely depleted, and surgical consultation and comprehensive medical management become the primary focus.

The emotional and psychological dimension of female hair loss is profound. Honest, stage-specific guidance matters especially here, making early intervention at Ludwig I–II particularly valuable. The psychological impact of hair loss on self-confidence and mental health is well documented, reinforcing why accurate, compassionate guidance at every stage matters. FUT surgery is also specifically noted as well suited for women in certain surgical contexts, reinforcing that a full spectrum of options should be evaluated at consultation.

Who Is NOT a PRP Candidate: Absolute and Relative Contraindications

Absolute contraindications (PRP is not appropriate): active scalp infections or dermatological conditions at the treatment site; blood clotting disorders or platelet dysfunction syndromes; patients currently on anticoagulant therapy; scarring alopecia such as lichen planopilaris or frontal fibrosing alopecia, where follicle destruction is permanent and inflammatory; and complete follicle loss in the treatment area.

Relative contraindications (PRP may be suboptimal or require further evaluation): active smokers, since smoking impairs platelet quality and growth factor potency; uncontrolled thyroid disease, which can affect hair cycling and diminish response; nutritional deficiencies such as iron deficiency anemia, which should be addressed before beginning treatment; and certain autoimmune conditions.

Disclosing these factors builds trust. Most competitor content omits contraindications, leaving patients to discover disqualifying factors only at consultation. A comprehensive medical evaluation, including bloodwork, scalp assessment, and medical history review, is essential before any PRP protocol begins.

PRP Within the Tiered Treatment Hierarchy: Where It Fits

Rather than competing with other treatments, PRP is best understood as a complementary component within a comprehensive, individualized plan. The most effective outcomes come from layering treatments strategically based on stage, goals, and medical profile.

Tier 1: Medical Therapies as the Foundation

Topical minoxidil and oral finasteride are the only FDA-approved therapies for androgenetic alopecia in men, and they remain the pharmacological foundation for managing progressive AGA.

PRP does not replace DHT-blocking medications for progressive androgenetic alopecia, a critical point most competitor content omits. PRP stimulates existing follicles; it does not address the hormonal cascade (DHT sensitivity) that drives ongoing miniaturization. For early-to-moderate patients, the recommended approach uses medical therapy as the base layer with PRP added as a regenerative amplifier. Studies show up to 50% better results when PRP is combined with minoxidil or low-level laser therapy (LLLT), a compelling argument for integrated planning. Patients looking to understand the full picture of how to slow hair loss progression will find that combining these modalities is consistently supported by the evidence.

Tier 2: PRP as a Standalone Regenerative Therapy

The optimal standalone application is Norwood I–III / Ludwig I–II patients with active follicles, no contraindications, and realistic expectations about gradual, cumulative improvement.

A standard protocol involves three to four initial sessions spaced four to six weeks apart, followed by maintenance sessions every six to twelve months. Results typically last 12 to 18 months before maintenance is needed. PRP is not a one-time cure; it is a maintenance-oriented therapy that requires ongoing commitment. Improvements build progressively across sessions, with peak results typically observed six to twelve months after the initial cycle. To state the limits plainly: PRP cannot restore hair in areas of complete follicle loss, cannot replace medical therapy for progressive AGA, and is not appropriate as the sole intervention for advanced stages.

Tier 3: PRP as a Surgical Adjunct to FUE Hair Transplantation

PRP’s most powerful and underreported application is as a pre-operative scalp primer and intra-operative adjunct to FUE hair transplantation. A 2025 systematic review of 217 hair transplant patients found that adding PRP was associated with improved hair density, enhanced follicle survival, and earlier initiation of hair growth post-FUE.

The mechanisms are clear: PRP improves scalp microcirculation before surgery, supports graft viability during the procedure, and reduces post-surgical shock loss (the temporary shedding that can follow transplantation). Understanding shock loss after hair transplant is important context for any patient considering surgery, and PRP’s role in mitigating this effect is one of its most clinically meaningful contributions. For surgical candidates (Norwood IV–VII), PRP as an adjunct is not a consolation prize; it is a clinical upgrade that can meaningfully improve outcomes. A 2026 review in Frontiers in Medicine confirms that adjunctive regenerative therapies including PRP are increasingly used to improve transplantation results.

A clinic with over 30 years of exclusive focus on hair restoration, led by physicians who co-authored the field’s definitive textbook, is uniquely positioned to integrate PRP as a surgical adjunct with the protocol rigor this application demands. That is the level of specialization Shapiro Medical Group brings to combined treatment planning.

What to Expect: The PRP Treatment Experience

The procedure follows a clear sequence: a blood draw from the patient’s arm, centrifugation to concentrate platelets to four to eight times normal levels, activation in evidence-based protocols, and injection into targeted scalp regions using fine needles. A typical session takes approximately 60 to 90 minutes from start to finish.

Immediately afterward, mild scalp sensitivity, minor swelling, and occasional temporary redness are normal and generally resolve within 24 to 48 hours. The overall safety profile is excellent: temporary scalp sensitivity occurs in roughly 15% of cases, mild swelling resolves within a day or two, and minor headache affects fewer than 10% of patients. No significant long-term adverse effects have been reported in the clinical literature, and the autologous nature of PRP eliminates the risk of allergic reaction.

Patients should not expect immediate dramatic changes. Initial improvements in texture and reduced shedding may appear within two to three months, meaningful density improvements typically become visible at four to six months, and peak results occur at six to twelve months. Sustaining those results requires maintenance sessions every six to twelve months; discontinuing treatment may lead to a gradual return to baseline.

Because there is no universally standardized protocol, the quality of the preparation system, the centrifugation approach, the activation method, and the injector’s anatomical expertise all directly influence outcomes. Provider selection is not a minor detail.

PRP vs. PRF vs. Exosomes: Understanding the Next-Generation Landscape

Patients increasingly encounter terms like PRF and exosome therapy in clinic marketing. Understanding the distinctions helps them ask sharper questions.

PRF (Platelet-Rich Fibrin) is a second-generation platelet concentrate that releases growth factors more slowly through a fibrin matrix, potentially offering more sustained delivery. It remains autologous, and its clinical evidence is growing but less extensive than PRP’s.

Exosome therapy is more mechanistically targeted, delivering cell-signaling vesicles that may influence follicle behavior at a molecular level. It still lacks FDA approval and the robust, large-scale clinical evidence base that PRP has accumulated across 43-plus RCTs.

PRP’s current advantage is precisely that evidence base. The landmark 2025 meta-analysis of 43 RCTs and 1,877 participants makes it the most evidence-supported regenerative option available today. An emerging innovation, photothermal PRP (published in Skin Health and Disease in December 2025), uses controlled electromagnetic energy to potentially enhance growth factor release and exosome production from PRP, signaling continued evolution of the therapy.

For most patients today, PRP remains the regenerative therapy with the strongest evidence. Emerging alternatives are best evaluated as the literature matures and discussed with a physician who stays current with the research.

The Honest Assessment: What PRP Can and Cannot Do

What PRP can do: stimulate dormant but viable follicles, extend the anagen phase, improve hair shaft thickness and density, slow the progression of early-to-moderate AGA, enhance outcomes when combined with medical therapy or surgical transplantation, and provide a natural, autologous option for those who prefer to avoid or cannot tolerate pharmaceuticals.

What PRP cannot do: restore hair where follicles are permanently lost, replace DHT-blocking medications for progressive AGA, match surgical transplantation for advanced loss, deliver permanent results without maintenance, or work effectively in patients with scarring alopecia, active infections, or significant contraindications.

Stated plainly, PRP achieves 70–80% success rates in early-to-moderate stages (Norwood I–III / Ludwig I–II) but drops to 30–40% for advanced loss (Norwood V+ or Ludwig III). This is not a failure of PRP; it is a biological reality reflecting the treatment’s mechanism.

This honesty matters. Patients who receive accurate, stage-appropriate expectations are more satisfied, more likely to maintain their protocol, and more likely to trust their provider even when results are incremental.

One additional point of transparency: while the centrifuge devices used to prepare PRP are FDA-cleared, PRP itself has not received FDA approval as a drug or biologic specifically for hair loss. This off-label use is standard, legal medical practice, similar to many established uses in medicine, but patients deserve to understand the distinction.

Conclusion: Matching the Right Treatment to the Right Stage

PRP hair restoration is a clinically validated, evidence-supported regenerative therapy, but its appropriateness and expected outcomes are fundamentally determined by hair loss stage. Early-to-moderate patients (Norwood I–III / Ludwig I–II) are the strongest standalone candidates. Advanced-loss patients are better served by PRP as a surgical adjunct to FUE. Nearly all patients benefit from an integrated plan built on a foundation of medical therapy.

The lack of protocol standardization, the activated versus non-activated distinction, the contraindication landscape, and the emerging alternatives all underscore that PRP is not a commodity treatment. Provider expertise and protocol rigor matter enormously. Self-assessment using the Norwood and Ludwig scales is a useful starting point, but a definitive candidacy determination requires a comprehensive evaluation by a physician with deep, specialized expertise. Tools like trichoscopy for hair loss diagnosis can provide an additional layer of precision in that assessment.

The evidence base continues to strengthen, combination protocols keep producing more compelling outcomes, and innovations like photothermal PRP signal continued advancement. For patients who act early, when follicles are still active and responsive, the opportunity for meaningful, lasting improvement is real.

Ready to Find Out If PRP Is Right for Your Stage? Consult the Experts at Shapiro Medical Group

The most important next step is not booking a PRP session. It is having a thorough, honest conversation with a physician who can accurately assess hair loss stage and recommend the right treatment hierarchy for each patient’s specific situation.

Shapiro Medical Group is uniquely qualified for that conversation. The practice has focused exclusively on hair restoration since 1990, representing more than 30 years of specialized experience. It is led by Dr. Ron Shapiro, co-author of the field’s definitive medical textbook, alongside a team that has lectured at over 100 conferences in more than 20 countries. The practice’s one-patient-per-day policy ensures every patient receives the full, undivided attention of the medical team.

Perhaps the most powerful endorsement of clinical excellence is this: physicians from other practices travel to Shapiro Medical Group both to learn advanced techniques and to have their own procedures performed there.

A consultation at Shapiro Medical Group encompasses surgical and non-surgical options, combination protocol planning, and honest stage-based candidacy assessment, not a one-size-fits-all recommendation. Whether patients are local to Minneapolis, Minnesota, traveling from out of state, or flying in from abroad, they can receive a personalized hair restoration consultation from one of the most credentialed teams in the field.

A consultation is an information-gathering conversation, not a commitment. The goal is to leave with clarity about where a patient stands, what realistic options are available, and what a treatment plan tailored to their stage and goals would look like.